vs
Side-by-side financial comparison of Axsome Therapeutics, Inc. (AXSM) and TOMPKINS FINANCIAL CORP (TMP). Click either name above to swap in a different company.
Axsome Therapeutics, Inc. is the larger business by last-quarter revenue ($196.0M vs $194.8M, roughly 1.0× TOMPKINS FINANCIAL CORP). TOMPKINS FINANCIAL CORP runs the higher net margin — 49.4% vs -14.6%, a 64.0% gap on every dollar of revenue. On growth, TOMPKINS FINANCIAL CORP posted the faster year-over-year revenue change (152.7% vs 65.0%). TOMPKINS FINANCIAL CORP produced more free cash flow last quarter ($31.9M vs $-18.7M). Over the past eight quarters, TOMPKINS FINANCIAL CORP's revenue compounded faster (63.6% CAGR vs 61.7%).
Jazz Pharmaceuticals plc is a global biopharmaceutical company with a focus on oncology and neuroscience. It was founded in 2003 in California, United States and is now headquartered in Dublin, Ireland.
Tompkins Financial Corporation is a small, diversified financial services company based in Ithaca, New York. It is the parent of the Tompkins Trust Company, as well as several other banks, an insurance agency, and a wealth management division.
AXSM vs TMP — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $196.0M | $194.8M |
| Net Profit | $-28.6M | $96.2M |
| Gross Margin | — | — |
| Operating Margin | -13.8% | 71.7% |
| Net Margin | -14.6% | 49.4% |
| Revenue YoY | 65.0% | 152.7% |
| Net Profit YoY | 61.9% | 388.9% |
| EPS (diluted) | $-0.55 | $6.72 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $196.0M | $194.8M | ||
| Q3 25 | $171.0M | $87.4M | ||
| Q2 25 | $150.0M | $82.6M | ||
| Q1 25 | $121.5M | $81.7M | ||
| Q4 24 | $118.8M | $77.1M | ||
| Q3 24 | $104.8M | $76.6M | ||
| Q2 24 | $87.2M | $72.7M | ||
| Q1 24 | $75.0M | $72.8M |
| Q4 25 | $-28.6M | $96.2M | ||
| Q3 25 | $-47.2M | $23.7M | ||
| Q2 25 | $-48.0M | $21.5M | ||
| Q1 25 | $-59.4M | $19.7M | ||
| Q4 24 | $-74.9M | $19.7M | ||
| Q3 24 | $-64.6M | $18.6M | ||
| Q2 24 | $-79.3M | $15.7M | ||
| Q1 24 | $-68.4M | $16.9M |
| Q4 25 | -13.8% | 71.7% | ||
| Q3 25 | -27.0% | 35.6% | ||
| Q2 25 | -24.5% | 34.2% | ||
| Q1 25 | -46.9% | 31.6% | ||
| Q4 24 | -61.1% | 33.4% | ||
| Q3 24 | -59.8% | 32.0% | ||
| Q2 24 | -89.5% | 28.3% | ||
| Q1 24 | -89.7% | 30.4% |
| Q4 25 | -14.6% | 49.4% | ||
| Q3 25 | -27.6% | 27.1% | ||
| Q2 25 | -32.0% | 26.0% | ||
| Q1 25 | -48.9% | 24.1% | ||
| Q4 24 | -63.1% | 25.5% | ||
| Q3 24 | -61.7% | 24.3% | ||
| Q2 24 | -91.0% | 21.6% | ||
| Q1 24 | -91.1% | 23.2% |
| Q4 25 | $-0.55 | $6.72 | ||
| Q3 25 | $-0.94 | $1.65 | ||
| Q2 25 | $-0.97 | $1.50 | ||
| Q1 25 | $-1.22 | $1.37 | ||
| Q4 24 | $-1.54 | $1.39 | ||
| Q3 24 | $-1.34 | $1.30 | ||
| Q2 24 | $-1.67 | $1.10 | ||
| Q1 24 | $-1.44 | $1.18 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $322.9M | $132.8M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $88.3M | $938.4M |
| Total Assets | $689.8M | $8.7B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $322.9M | $132.8M | ||
| Q3 25 | $325.3M | $193.5M | ||
| Q2 25 | $303.0M | $212.6M | ||
| Q1 25 | $300.9M | $193.1M | ||
| Q4 24 | $315.4M | $134.4M | ||
| Q3 24 | $327.3M | $132.3M | ||
| Q2 24 | $315.7M | $70.9M | ||
| Q1 24 | $331.4M | $57.1M |
| Q4 25 | $88.3M | $938.4M | ||
| Q3 25 | $73.7M | $788.8M | ||
| Q2 25 | $73.1M | $761.8M | ||
| Q1 25 | $53.2M | $741.4M | ||
| Q4 24 | $57.0M | $713.4M | ||
| Q3 24 | $92.9M | $719.9M | ||
| Q2 24 | $102.9M | $674.6M | ||
| Q1 24 | $144.0M | $667.9M |
| Q4 25 | $689.8M | $8.7B | ||
| Q3 25 | $669.3M | $8.5B | ||
| Q2 25 | $639.8M | $8.4B | ||
| Q1 25 | $596.7M | $8.2B | ||
| Q4 24 | $568.5M | $8.1B | ||
| Q3 24 | $561.5M | $8.0B | ||
| Q2 24 | $548.2M | $7.9B | ||
| Q1 24 | $545.7M | $7.8B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-18.7M | $38.9M |
| Free Cash FlowOCF − Capex | $-18.7M | $31.9M |
| FCF MarginFCF / Revenue | -9.6% | 16.4% |
| Capex IntensityCapex / Revenue | 0.0% | 3.6% |
| Cash ConversionOCF / Net Profit | — | 0.40× |
| TTM Free Cash FlowTrailing 4 quarters | $-93.9M | $105.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-18.7M | $38.9M | ||
| Q3 25 | $1.0M | $34.9M | ||
| Q2 25 | $-32.4M | $18.9M | ||
| Q1 25 | $-43.4M | $22.2M | ||
| Q4 24 | $-26.2M | $95.0M | ||
| Q3 24 | $-18.6M | $21.2M | ||
| Q2 24 | $-30.1M | $27.3M | ||
| Q1 24 | $-53.5M | $23.2M |
| Q4 25 | $-18.7M | $31.9M | ||
| Q3 25 | $988.0K | $33.9M | ||
| Q2 25 | $-32.4M | $18.3M | ||
| Q1 25 | $-43.7M | $20.9M | ||
| Q4 24 | $-26.2M | $88.8M | ||
| Q3 24 | $-18.7M | $18.9M | ||
| Q2 24 | $-30.2M | $26.3M | ||
| Q1 24 | $-53.6M | $21.9M |
| Q4 25 | -9.6% | 16.4% | ||
| Q3 25 | 0.6% | 38.8% | ||
| Q2 25 | -21.6% | 22.1% | ||
| Q1 25 | -36.0% | 25.5% | ||
| Q4 24 | -22.1% | 115.1% | ||
| Q3 24 | -17.9% | 24.7% | ||
| Q2 24 | -34.6% | 36.2% | ||
| Q1 24 | -71.4% | 30.0% |
| Q4 25 | 0.0% | 3.6% | ||
| Q3 25 | 0.0% | 1.1% | ||
| Q2 25 | 0.0% | 0.8% | ||
| Q1 25 | 0.3% | 1.7% | ||
| Q4 24 | 0.0% | 8.1% | ||
| Q3 24 | 0.1% | 2.9% | ||
| Q2 24 | 0.1% | 1.3% | ||
| Q1 24 | 0.1% | 1.9% |
| Q4 25 | — | 0.40× | ||
| Q3 25 | — | 1.47× | ||
| Q2 25 | — | 0.88× | ||
| Q1 25 | — | 1.13× | ||
| Q4 24 | — | 4.82× | ||
| Q3 24 | — | 1.14× | ||
| Q2 24 | — | 1.74× | ||
| Q1 24 | — | 1.38× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
